HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical predictors of acute response with quetiapine in psychotic mood disorders.

AbstractBACKGROUND:
In controlled studies of patients with schizophrenia, the atypical antipsychotic quetiapine, 300 mg/day, has been shown to be as effective in the treatment of positive and negative symptoms as haloperidol. However, little is known about the efficacy of quetiapine in patients with psychotic mood disorders. The purpose of this study was to assess the efficacy of quetiapine in the treatment of psychotic mood disorders in comparison with nonaffective psychotic disorders and identify clinical factors associated with quetiapine response.
METHOD:
In a naturalistic setting, by reviewing medical records, we assessed response to quetiapine and factors associated with response to quetiapine in 145 consecutive patients newly treated with the drug at a nonprofit academic psychiatric hospital. These patients had received a discharge diagnosis of bipolar disorder (manic, mixed, or depressive type), major depression with psychotic features, schizophrenia, schizoaffective disorder (bipolar or depressive type), delusional disorder, or psychosis not otherwise specified (NOS) according to DSM-IV criteria.
RESULTS:
Patients with a diagnosis of bipolar disorder, manic, mixed, or depressed and schizoaffective disorder, bipolar type displayed higher response rates (> 74%) compared with patients with schizophrenia. However, this finding did not achieve statistical significance. A diagnosis of major depression with psychotic features (p = .02) and longer duration of illness (p = .03) were associated with less chance of responding.
CONCLUSION:
Quetiapine may be a useful alternative or adjunctive treatment for patients with bipolar and schizoaffective disorders.
AuthorsC A Zarate Jr, A Rothschild, K E Fletcher, A Madrid, J Zapatel
JournalThe Journal of clinical psychiatry (J Clin Psychiatry) Vol. 61 Issue 3 Pg. 185-9 (Mar 2000) ISSN: 0160-6689 [Print] United States
PMID10817103 (Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antipsychotic Agents
  • Dibenzothiazepines
  • Quetiapine Fumarate
Topics
  • Adult
  • Affective Disorders, Psychotic (diagnosis, drug therapy, psychology)
  • Antipsychotic Agents (therapeutic use)
  • Bipolar Disorder (drug therapy, psychology)
  • Chronic Disease
  • Depressive Disorder (drug therapy, psychology)
  • Dibenzothiazepines (therapeutic use)
  • Female
  • Hospital Records
  • Humans
  • Male
  • Prognosis
  • Psychotic Disorders (drug therapy, psychology)
  • Quetiapine Fumarate
  • Retrospective Studies
  • Schizophrenia (drug therapy)
  • Schizophrenia, Paranoid (drug therapy, psychology)
  • Schizophrenic Psychology
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: